Sydney, June 24, 2026, 03:08 AEST
CSL Ltd slipped 0.7% to end at A$112.04 Tuesday. Shares hit A$115.80 during the session but closed just 35 cents above their low for the day. The S&P/ASX 200 dropped 0.3% to 8,787.
CSL’s two-day slide wiped out A$4.28, a bit more than half of Friday’s A$8.24 jump. No new ASX filings have shown up on CSL’s investor site since June 9. That points to the fall coming from some caution on the early-stage turnaround, not fresh news from the company.
Australian shares fell for the fourth day, losing ground as early gains faded with weaker U.S. futures and a rise in bond yields. Risk appetite faded as traders waited for inflation numbers due Wednesday and jobs data on Thursday.
CSL is still off 54% for the past year, even after last week’s rally. Back in April, Hebe Chen at Vantage Markets flagged worries about “slowing earnings momentum, a more volatile vaccine segment” and not much visibility on strategy. Trading Economics
CSL cut its fiscal 2026 outlook in May, triggering fresh worries. The Melbourne-based biotech now sees revenue at about US$15.2 billion and NPATA around US$3.1 billion at constant currency, which removes exchange-rate effects. NPATA is a profit figure that leaves out amortisation of acquired IP and big one-off items.
CSL’s interim CEO Gordon Naylor said, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.” The company still expects demand for immunoglobulin products to rise. CSL is cutting down on surplus inventory in U.S. distribution channels.
The downside risk is still big. CSL says U.S. inventory normalisation could shave about US$300 million from full-year revenue, falling albumin prices in China will knock off around US$200 million, and there are more headwinds stripping another US$150 million. Non-cash, pre-tax impairments are also in the mix, with CSL forecasting about US$5 billion of accounting write-downs through fiscal 2026 and 2027. These do not mean an immediate cash outflow.
Grifols, the Spanish plasma-products company, isn’t easing up on competition. The company expects adjusted core earnings to climb more than 25% in 2026 as it pushes for higher profits and works to cut debt. Over at Takeda, the focus is on regulatory filings for TAK-881 this year. The new immunoglobulin treatment is pitched as requiring less volume and shorter administration than the company’s HyQvia therapy.
CSL says the hunt for a permanent CEO is still ongoing. The company named Diego Sacristan as chief commercial officer for CSL Behring and CSL Vifor, with Sacristan stepping into the role on July 1. CSL also said Naylor is likely to stay on the board after the next CEO is in place.
Australia’s May CPI numbers land at 11:30 a.m. AEST on Wednesday, with jobs data set for the same time Thursday. CSL holders are looking to August 18, when the company is set to release full-year financials and operating results.
